This phase II trial aims to understand how safe and effective it is to use a combination of chemotherapy, immunotherapy and chest radiation therapy to treat extensive stage small cell lung cancer.
This trial is treating patients with extensive stage small cell lung cancer.
This is a systemic therapy and radiation therapy trial.
You may be able to join this trial if:
- You have been diagnosed with cancer, but have not received any treatment.
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A phase II study of platinum and etoposide chemotherapy, durvalumab with thoracic radiotherapy in the first line treatment of patients with extensive-stage small-cell lung cancer
This is a single arm study. Eligible participants will receive durvalumab (immunotherapy) at the same time as 4-cycles of cisplatin/carboplatin and etopside chemotherapy, which will be given as an injection every three weeks for up to 12 weeks. Maintenance therapy with durvalumab will continue for 4 weeks once the chemotherapy cycles have been completed, until there is evidence of disease progression. Participants will also receive 10 chest radiotherapy sessions, which will take approx. 2 weeks to complete (given either concurrently with cycle 3 or 4 of chemotherapy (called concurrent radiotherapy) or within 6 weeks of finishing chemotherapy (called consolidation radiotherapy). Participants will be monitored throughout the study, for any adverse events or for progression of disease.
Recruiting Hospitals Read More